Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Sihuan Pharma Plans to Bring Anti-Infective Generics from India's Hetero Lab to China

publication date: Feb 12, 2020

Sihuan Pharma and Hetero Labs, an Indian generic drug maker, have signed a framework cooperation agreement to bring Hetero's products -- including potential COVID-19 anti-infectives -- to China. Hetero claims to be the leading producer of anti-retroviral drugs for HIV/AIDS, serving 40% of the HIV/AIDS population globally with 30 anti-retroviral product combinations. Sihuan, a novel drug company, will make and distribute Hetero's generic products in China. More details....

Stock Symbol: (HKEX: 0460)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital